Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive postmenopausal early breast cancer.

Trial Profile

Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive postmenopausal early breast cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2017

At a glance

  • Drugs Celecoxib (Primary) ; Exemestane; Letrozole
  • Indications Early breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms NEO-EXCEL
  • Most Recent Events

    • 12 Dec 2015 Status changed from active, no longer recruiting to completed, as per an abstract presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 12 Dec 2015 Primary endpoint has been met (Objective clinical response), as per an abstract presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top